Robert Freedman
Concepts (537)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schizophrenia | 72 | 2020 | 476 | 8.600 |
Why?
| | Choline | 12 | 2024 | 134 | 4.570 |
Why?
| | Evoked Potentials, Auditory | 39 | 2024 | 179 | 3.550 |
Why?
| | Receptors, Nicotinic | 37 | 2013 | 327 | 3.350 |
Why?
| | Nicotinic Agonists | 15 | 2016 | 135 | 3.220 |
Why?
| | Brain | 35 | 2021 | 2981 | 2.380 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 24 | 2016 | 94 | 2.250 |
Why?
| | Hippocampus | 31 | 2013 | 986 | 1.960 |
Why?
| | Psychotic Disorders | 9 | 2021 | 181 | 1.850 |
Why?
| | Hot Flashes | 7 | 2014 | 92 | 1.790 |
Why?
| | Prenatal Exposure Delayed Effects | 8 | 2021 | 662 | 1.790 |
Why?
| | Neural Inhibition | 17 | 2013 | 180 | 1.700 |
Why?
| | Sensory Gating | 8 | 2020 | 44 | 1.700 |
Why?
| | Psychiatry | 5 | 2018 | 182 | 1.700 |
Why?
| | Benzylidene Compounds | 8 | 2013 | 20 | 1.640 |
Why?
| | Schizophrenic Psychology | 19 | 2015 | 100 | 1.640 |
Why?
| | Periodicals as Topic | 5 | 2018 | 209 | 1.590 |
Why?
| | Folic Acid | 4 | 2024 | 197 | 1.470 |
Why?
| | Pregnancy Complications, Infectious | 4 | 2021 | 437 | 1.410 |
Why?
| | Fetal Development | 9 | 2024 | 296 | 1.400 |
Why?
| | Nicotine | 17 | 2013 | 334 | 1.390 |
Why?
| | Pyridines | 8 | 2013 | 606 | 1.200 |
Why?
| | Antidepressive Agents | 3 | 2023 | 234 | 1.170 |
Why?
| | Chromosomes, Human, Pair 15 | 16 | 2015 | 50 | 1.150 |
Why?
| | Attention | 18 | 2020 | 459 | 1.150 |
Why?
| | Ketamine | 2 | 2023 | 141 | 1.110 |
Why?
| | Gestational Age | 6 | 2024 | 989 | 1.080 |
Why?
| | Pursuit, Smooth | 9 | 2007 | 19 | 1.070 |
Why?
| | Maternal Exposure | 2 | 2019 | 189 | 1.020 |
Why?
| | Pregnancy | 18 | 2024 | 7217 | 0.910 |
Why?
| | Acoustic Stimulation | 20 | 2020 | 322 | 0.900 |
Why?
| | Menopause | 4 | 2014 | 327 | 0.880 |
Why?
| | Mental Disorders | 5 | 2021 | 1133 | 0.840 |
Why?
| | Evoked Potentials | 7 | 2020 | 132 | 0.810 |
Why?
| | Child Behavior | 2 | 2016 | 234 | 0.790 |
Why?
| | Child Development | 5 | 2024 | 481 | 0.780 |
Why?
| | Electroconvulsive Therapy | 1 | 2023 | 17 | 0.770 |
Why?
| | Dietary Supplements | 5 | 2021 | 586 | 0.760 |
Why?
| | Humans | 126 | 2024 | 145625 | 0.750 |
Why?
| | Auditory Perception | 8 | 2004 | 107 | 0.750 |
Why?
| | Prenatal Care | 4 | 2021 | 310 | 0.740 |
Why?
| | Body Temperature Regulation | 4 | 2013 | 106 | 0.710 |
Why?
| | Infant, Small for Gestational Age | 1 | 2022 | 118 | 0.700 |
Why?
| | Reflex, Startle | 3 | 2014 | 74 | 0.700 |
Why?
| | Antipsychotic Agents | 8 | 2008 | 178 | 0.690 |
Why?
| | Phosphatidylcholines | 3 | 2018 | 130 | 0.690 |
Why?
| | Micronutrients | 2 | 2021 | 102 | 0.670 |
Why?
| | Infant Behavior | 2 | 2020 | 28 | 0.660 |
Why?
| | Infant, Newborn | 10 | 2024 | 6449 | 0.640 |
Why?
| | Female | 75 | 2024 | 79080 | 0.630 |
Why?
| | Smoking | 14 | 2013 | 1478 | 0.630 |
Why?
| | Brain Mapping | 6 | 2013 | 540 | 0.620 |
Why?
| | Adult | 55 | 2024 | 40821 | 0.600 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 2 | 2018 | 46 | 0.590 |
Why?
| | Prefrontal Cortex | 3 | 2016 | 338 | 0.580 |
Why?
| | Neurons | 10 | 2019 | 1663 | 0.580 |
Why?
| | Editorial Policies | 2 | 2018 | 45 | 0.570 |
Why?
| | Hallucinogens | 1 | 2021 | 112 | 0.560 |
Why?
| | Magnetic Resonance Imaging | 13 | 2013 | 3917 | 0.560 |
Why?
| | Perceptual Disorders | 3 | 2005 | 24 | 0.560 |
Why?
| | Endophenotypes | 2 | 2015 | 24 | 0.560 |
Why?
| | Saccades | 7 | 2007 | 45 | 0.550 |
Why?
| | Electroencephalography | 11 | 2020 | 570 | 0.540 |
Why?
| | Male | 79 | 2024 | 73014 | 0.540 |
Why?
| | Hydrocortisone | 1 | 2020 | 303 | 0.540 |
Why?
| | C-Reactive Protein | 4 | 2022 | 427 | 0.540 |
Why?
| | Nootropic Agents | 2 | 2020 | 30 | 0.530 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.500 |
Why?
| | Premature Birth | 1 | 2021 | 389 | 0.500 |
Why?
| | Problem Behavior | 1 | 2018 | 97 | 0.490 |
Why?
| | Interneurons | 6 | 2001 | 124 | 0.470 |
Why?
| | Arousal | 6 | 1993 | 157 | 0.470 |
Why?
| | Primary Prevention | 1 | 2018 | 222 | 0.470 |
Why?
| | Image Processing, Computer-Assisted | 6 | 2013 | 774 | 0.470 |
Why?
| | Marijuana Smoking | 1 | 2019 | 248 | 0.460 |
Why?
| | Depression | 2 | 2023 | 1566 | 0.460 |
Why?
| | Psychological Trauma | 1 | 2016 | 58 | 0.460 |
Why?
| | Validation Studies as Topic | 1 | 2015 | 23 | 0.450 |
Why?
| | Afferent Pathways | 3 | 2013 | 46 | 0.440 |
Why?
| | Cognition Disorders | 3 | 2010 | 547 | 0.430 |
Why?
| | Bungarotoxins | 10 | 2008 | 45 | 0.430 |
Why?
| | Amygdala | 1 | 2016 | 194 | 0.420 |
Why?
| | Genotype | 9 | 2015 | 1866 | 0.420 |
Why?
| | Aggression | 1 | 2016 | 170 | 0.420 |
Why?
| | Sleep | 4 | 2014 | 896 | 0.420 |
Why?
| | Sleep, REM | 3 | 2006 | 44 | 0.410 |
Why?
| | Reaction Time | 7 | 2020 | 434 | 0.400 |
Why?
| | Cannabis | 1 | 2021 | 519 | 0.390 |
Why?
| | Teaching | 1 | 2016 | 243 | 0.390 |
Why?
| | Eye Movements | 4 | 2013 | 91 | 0.380 |
Why?
| | Phosphorylcholine | 1 | 2013 | 19 | 0.380 |
Why?
| | Gyrus Cinguli | 4 | 2006 | 97 | 0.380 |
Why?
| | Sleep Apnea Syndromes | 1 | 2014 | 98 | 0.380 |
Why?
| | Neural Pathways | 4 | 2010 | 318 | 0.370 |
Why?
| | Genetic Linkage | 10 | 2012 | 269 | 0.370 |
Why?
| | Mothers | 5 | 2021 | 771 | 0.360 |
Why?
| | Double-Blind Method | 6 | 2016 | 2064 | 0.350 |
Why?
| | Neuropsychological Tests | 6 | 2016 | 1136 | 0.350 |
Why?
| | Clozapine | 4 | 2004 | 19 | 0.340 |
Why?
| | Ocular Motility Disorders | 2 | 2004 | 42 | 0.340 |
Why?
| | Autism Spectrum Disorder | 1 | 2016 | 404 | 0.340 |
Why?
| | Cerebral Cortex | 6 | 2006 | 481 | 0.330 |
Why?
| | Emotions | 2 | 2016 | 555 | 0.330 |
Why?
| | Nicotinic Antagonists | 6 | 2008 | 36 | 0.310 |
Why?
| | 5-Hydroxytryptophan | 1 | 2009 | 19 | 0.310 |
Why?
| | Middle Aged | 30 | 2016 | 36359 | 0.300 |
Why?
| | Dopamine | 7 | 2009 | 295 | 0.300 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2009 | 44 | 0.300 |
Why?
| | Schizotypal Personality Disorder | 2 | 2002 | 11 | 0.300 |
Why?
| | Cognition | 3 | 2016 | 1286 | 0.300 |
Why?
| | Sensation Disorders | 2 | 2007 | 37 | 0.290 |
Why?
| | Peer Review, Research | 1 | 2009 | 36 | 0.290 |
Why?
| | Fetus | 4 | 2021 | 798 | 0.290 |
Why?
| | Cocaine-Related Disorders | 2 | 2001 | 132 | 0.290 |
Why?
| | Infant | 9 | 2021 | 10093 | 0.280 |
Why?
| | Thalamus | 2 | 2007 | 132 | 0.280 |
Why?
| | Biomedical Research | 1 | 2015 | 724 | 0.280 |
Why?
| | Mice, Inbred DBA | 4 | 2008 | 185 | 0.280 |
Why?
| | Nitric Oxide Synthase | 2 | 2000 | 233 | 0.280 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2007 | 184 | 0.270 |
Why?
| | Writing | 1 | 2009 | 101 | 0.270 |
Why?
| | Body Temperature | 2 | 2007 | 227 | 0.270 |
Why?
| | Sensory Aids | 1 | 2007 | 4 | 0.260 |
Why?
| | Miniaturization | 1 | 2007 | 22 | 0.260 |
Why?
| | Child, Preschool | 6 | 2024 | 11888 | 0.260 |
Why?
| | Neurons, Afferent | 2 | 1999 | 102 | 0.250 |
Why?
| | Auditory Perceptual Disorders | 3 | 2008 | 7 | 0.250 |
Why?
| | Equipment and Supplies | 1 | 2007 | 36 | 0.250 |
Why?
| | Neostriatum | 1 | 2007 | 37 | 0.250 |
Why?
| | Synaptic Transmission | 6 | 2024 | 292 | 0.250 |
Why?
| | Humidity | 1 | 2007 | 50 | 0.250 |
Why?
| | Learning | 2 | 2009 | 446 | 0.250 |
Why?
| | Contingent Negative Variation | 2 | 2005 | 9 | 0.240 |
Why?
| | Phenotype | 7 | 2018 | 3186 | 0.240 |
Why?
| | Genetic Markers | 7 | 2012 | 337 | 0.240 |
Why?
| | Child of Impaired Parents | 2 | 1996 | 38 | 0.240 |
Why?
| | Pedigree | 8 | 2009 | 507 | 0.240 |
Why?
| | Acetylcholine | 3 | 2002 | 208 | 0.230 |
Why?
| | Adrenergic Uptake Inhibitors | 1 | 2005 | 14 | 0.230 |
Why?
| | N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2005 | 11 | 0.230 |
Why?
| | Ganglionic Stimulants | 1 | 2005 | 15 | 0.230 |
Why?
| | Biomarkers | 3 | 2015 | 4329 | 0.230 |
Why?
| | Animals | 35 | 2021 | 38030 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 6 | 2013 | 2455 | 0.220 |
Why?
| | Internship and Residency | 1 | 2016 | 1269 | 0.220 |
Why?
| | Sensation | 3 | 1991 | 56 | 0.220 |
Why?
| | Galvanic Skin Response | 3 | 2013 | 26 | 0.220 |
Why?
| | Child | 9 | 2021 | 22638 | 0.220 |
Why?
| | Receptors, Cholinergic | 5 | 2009 | 42 | 0.220 |
Why?
| | Reference Values | 8 | 2002 | 787 | 0.210 |
Why?
| | Time Perception | 1 | 2005 | 31 | 0.210 |
Why?
| | Mice, Inbred C3H | 2 | 2001 | 252 | 0.210 |
Why?
| | Cross-Over Studies | 3 | 2016 | 612 | 0.200 |
Why?
| | Sleep Deprivation | 1 | 2006 | 207 | 0.200 |
Why?
| | Norepinephrine | 5 | 1992 | 201 | 0.190 |
Why?
| | Young Adult | 5 | 2022 | 14240 | 0.190 |
Why?
| | Pyramidal Cells | 3 | 2003 | 80 | 0.190 |
Why?
| | Bipolar Disorder | 4 | 2007 | 281 | 0.190 |
Why?
| | Echo-Planar Imaging | 1 | 2002 | 24 | 0.190 |
Why?
| | Homovanillic Acid | 5 | 1990 | 10 | 0.190 |
Why?
| | Promoter Regions, Genetic | 4 | 2003 | 1236 | 0.180 |
Why?
| | Publishing | 2 | 2016 | 115 | 0.170 |
Why?
| | Wakefulness | 2 | 2001 | 169 | 0.170 |
Why?
| | Linkage Disequilibrium | 2 | 2009 | 257 | 0.170 |
Why?
| | Rats | 16 | 2002 | 5574 | 0.170 |
Why?
| | Hearing Disorders | 1 | 2001 | 7 | 0.170 |
Why?
| | Social Problems | 1 | 2021 | 12 | 0.170 |
Why?
| | Phencyclidine | 3 | 1992 | 4 | 0.160 |
Why?
| | Vitamin A | 1 | 2021 | 60 | 0.160 |
Why?
| | Reward | 1 | 2023 | 242 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2010 | 2018 | 0.160 |
Why?
| | Vitamin D | 2 | 2021 | 402 | 0.160 |
Why?
| | Frontal Lobe | 3 | 2006 | 159 | 0.160 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2021 | 145 | 0.160 |
Why?
| | Oxygen | 3 | 2013 | 996 | 0.160 |
Why?
| | Sweating | 2 | 2013 | 43 | 0.150 |
Why?
| | Gene Expression Regulation | 3 | 2015 | 2591 | 0.150 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 2 | 2004 | 421 | 0.150 |
Why?
| | Object Attachment | 1 | 2020 | 48 | 0.150 |
Why?
| | Chromosome Mapping | 4 | 2009 | 505 | 0.150 |
Why?
| | Vitamins | 1 | 2021 | 183 | 0.150 |
Why?
| | Analysis of Variance | 5 | 2008 | 1293 | 0.150 |
Why?
| | Schizophrenia, Childhood | 1 | 1999 | 3 | 0.150 |
Why?
| | Psychiatric Status Rating Scales | 4 | 2005 | 512 | 0.150 |
Why?
| | Bombesin | 1 | 1999 | 10 | 0.140 |
Why?
| | Pituitary-Adrenal System | 1 | 2020 | 169 | 0.140 |
Why?
| | Genetic Variation | 3 | 2003 | 992 | 0.140 |
Why?
| | Rats, Sprague-Dawley | 8 | 2002 | 2533 | 0.140 |
Why?
| | Alleles | 5 | 2009 | 900 | 0.140 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2020 | 204 | 0.140 |
Why?
| | Maternal Age | 1 | 2019 | 129 | 0.140 |
Why?
| | Logistic Models | 2 | 2022 | 2112 | 0.140 |
Why?
| | Disease Models, Animal | 8 | 2009 | 4565 | 0.140 |
Why?
| | Nutritional Status | 1 | 2021 | 344 | 0.140 |
Why?
| | Catecholamines | 3 | 2002 | 88 | 0.140 |
Why?
| | DNA Mutational Analysis | 3 | 2013 | 409 | 0.140 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2013 | 50 | 0.140 |
Why?
| | Stem Cells | 1 | 2002 | 612 | 0.140 |
Why?
| | Psychomotor Performance | 4 | 2005 | 325 | 0.140 |
Why?
| | Irritable Mood | 1 | 2018 | 30 | 0.130 |
Why?
| | Risk Factors | 10 | 2021 | 10840 | 0.130 |
Why?
| | RNA, Messenger | 7 | 2006 | 2783 | 0.130 |
Why?
| | History, 21st Century | 1 | 2018 | 224 | 0.130 |
Why?
| | Dentate Gyrus | 1 | 1997 | 41 | 0.130 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2002 | 899 | 0.130 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2012 | 2228 | 0.130 |
Why?
| | Postmortem Changes | 3 | 2006 | 15 | 0.130 |
Why?
| | Adolescent | 12 | 2017 | 22451 | 0.130 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2017 | 30 | 0.130 |
Why?
| | Family | 4 | 2015 | 680 | 0.120 |
Why?
| | Urinary Tract Infections | 1 | 2019 | 207 | 0.120 |
Why?
| | Gene Expression | 5 | 2006 | 1461 | 0.120 |
Why?
| | Neurocognitive Disorders | 1 | 1996 | 33 | 0.120 |
Why?
| | Data Interpretation, Statistical | 1 | 1998 | 365 | 0.120 |
Why?
| | Electrophysiology | 6 | 2003 | 219 | 0.120 |
Why?
| | Chewing Gum | 2 | 2007 | 8 | 0.120 |
Why?
| | Skin Temperature | 2 | 2006 | 36 | 0.120 |
Why?
| | Prepulse Inhibition | 1 | 2015 | 12 | 0.110 |
Why?
| | Nitric Oxide | 1 | 2000 | 883 | 0.110 |
Why?
| | Vanilmandelic Acid | 4 | 1990 | 4 | 0.110 |
Why?
| | Methoxyhydroxyphenylglycol | 4 | 1990 | 13 | 0.110 |
Why?
| | Benzodiazepines | 2 | 2008 | 156 | 0.110 |
Why?
| | Treatment Outcome | 2 | 2023 | 11744 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 379 | 0.110 |
Why?
| | Cell Differentiation | 1 | 2002 | 1979 | 0.110 |
Why?
| | Pandemics | 2 | 2021 | 1700 | 0.110 |
Why?
| | Twins | 1 | 1996 | 156 | 0.110 |
Why?
| | Signal Processing, Computer-Assisted | 2 | 2013 | 151 | 0.110 |
Why?
| | Respiratory Tract Infections | 1 | 2019 | 399 | 0.100 |
Why?
| | Electromyography | 3 | 2005 | 417 | 0.100 |
Why?
| | Postmenopause | 2 | 2007 | 394 | 0.100 |
Why?
| | Snoring | 1 | 2014 | 19 | 0.100 |
Why?
| | Cerebrovascular Circulation | 2 | 2007 | 293 | 0.100 |
Why?
| | Synapsins | 1 | 1993 | 13 | 0.100 |
Why?
| | Synaptophysin | 1 | 1993 | 15 | 0.100 |
Why?
| | Hot Temperature | 2 | 2007 | 396 | 0.100 |
Why?
| | Clonidine | 1 | 2013 | 34 | 0.100 |
Why?
| | Polymorphism, Genetic | 4 | 2009 | 611 | 0.100 |
Why?
| | Corpus Striatum | 2 | 1992 | 181 | 0.100 |
Why?
| | Cerebellum | 5 | 2002 | 225 | 0.100 |
Why?
| | Polymorphism, Single-Stranded Conformational | 2 | 2003 | 26 | 0.100 |
Why?
| | Sleep Stages | 1 | 1993 | 76 | 0.100 |
Why?
| | Brain Tissue Transplantation | 1 | 1992 | 19 | 0.090 |
Why?
| | Fetal Tissue Transplantation | 1 | 1992 | 33 | 0.090 |
Why?
| | Mesencephalon | 1 | 1992 | 65 | 0.090 |
Why?
| | Zinc | 1 | 1995 | 310 | 0.090 |
Why?
| | Estrogen Replacement Therapy | 1 | 2013 | 144 | 0.090 |
Why?
| | Parasympathetic Nervous System | 1 | 1992 | 26 | 0.090 |
Why?
| | Auditory Pathways | 1 | 1992 | 53 | 0.090 |
Why?
| | Heart Rate | 2 | 2007 | 844 | 0.090 |
Why?
| | Perinatal Care | 1 | 2013 | 61 | 0.090 |
Why?
| | Functional Laterality | 1 | 2013 | 240 | 0.090 |
Why?
| | Genomics | 1 | 2018 | 851 | 0.090 |
Why?
| | Immunity | 1 | 2013 | 140 | 0.090 |
Why?
| | Iodine Radioisotopes | 4 | 2001 | 139 | 0.090 |
Why?
| | gamma-Aminobutyric Acid | 3 | 2003 | 195 | 0.090 |
Why?
| | Gene Frequency | 2 | 2005 | 495 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2015 | 2910 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2020 | 1169 | 0.090 |
Why?
| | Inflammation | 2 | 2021 | 2915 | 0.090 |
Why?
| | Alcoholism | 3 | 2003 | 830 | 0.090 |
Why?
| | Gene Duplication | 3 | 2015 | 67 | 0.080 |
Why?
| | Blood Pressure | 3 | 2007 | 1761 | 0.080 |
Why?
| | United States | 3 | 2018 | 16041 | 0.080 |
Why?
| | Pregnancy Complications | 2 | 2019 | 605 | 0.080 |
Why?
| | Circadian Rhythm | 2 | 2013 | 514 | 0.080 |
Why?
| | Memory | 1 | 2013 | 298 | 0.080 |
Why?
| | Administration, Oral | 2 | 2005 | 867 | 0.080 |
Why?
| | Event-Related Potentials, P300 | 2 | 2003 | 17 | 0.080 |
Why?
| | Time Factors | 4 | 2005 | 7079 | 0.080 |
Why?
| | Aged | 10 | 2015 | 26251 | 0.080 |
Why?
| | Genetic Association Studies | 1 | 2012 | 376 | 0.080 |
Why?
| | Photic Stimulation | 2 | 2002 | 265 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2012 | 3633 | 0.080 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2014 | 300 | 0.070 |
Why?
| | Mice | 8 | 2009 | 18266 | 0.070 |
Why?
| | Electrooculography | 2 | 2001 | 12 | 0.070 |
Why?
| | Anxiety Disorders | 1 | 2012 | 351 | 0.070 |
Why?
| | Alprazolam | 1 | 1988 | 6 | 0.070 |
Why?
| | Sequence Deletion | 1 | 2009 | 190 | 0.070 |
Why?
| | Education, Distance | 1 | 2009 | 59 | 0.070 |
Why?
| | Lorazepam | 1 | 1988 | 24 | 0.070 |
Why?
| | Diazepam | 1 | 1988 | 32 | 0.070 |
Why?
| | Field Dependence-Independence | 1 | 2008 | 6 | 0.070 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2009 | 90 | 0.070 |
Why?
| | Rats, Inbred Strains | 6 | 1992 | 316 | 0.070 |
Why?
| | Brief Psychiatric Rating Scale | 1 | 2008 | 7 | 0.070 |
Why?
| | Glycols | 1 | 1988 | 5 | 0.070 |
Why?
| | Risk | 2 | 2002 | 917 | 0.070 |
Why?
| | Evoked Potentials, Somatosensory | 1 | 1988 | 39 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2013 | 5397 | 0.070 |
Why?
| | Dihydro-beta-Erythroidine | 2 | 2008 | 6 | 0.070 |
Why?
| | Genes | 2 | 1998 | 215 | 0.060 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 5875 | 0.060 |
Why?
| | Nerve Net | 2 | 2002 | 284 | 0.060 |
Why?
| | Diseases in Twins | 1 | 1988 | 114 | 0.060 |
Why?
| | Quality Improvement | 1 | 2016 | 1325 | 0.060 |
Why?
| | Depressive Disorder | 1 | 1990 | 359 | 0.060 |
Why?
| | Auditory Cortex | 1 | 2007 | 46 | 0.060 |
Why?
| | Models, Neurological | 2 | 2000 | 252 | 0.060 |
Why?
| | Microsatellite Repeats | 2 | 2012 | 159 | 0.060 |
Why?
| | Prospective Studies | 1 | 2019 | 8087 | 0.060 |
Why?
| | Monitoring, Ambulatory | 1 | 2007 | 88 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1754 | 0.060 |
Why?
| | Drug Administration Schedule | 1 | 2008 | 782 | 0.060 |
Why?
| | Parkinson Disease | 1 | 1992 | 614 | 0.060 |
Why?
| | Drug Interactions | 2 | 2008 | 403 | 0.060 |
Why?
| | Telemetry | 1 | 2005 | 40 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2007 | 1992 | 0.060 |
Why?
| | Genome | 2 | 2006 | 307 | 0.060 |
Why?
| | Memory, Short-Term | 1 | 2008 | 272 | 0.060 |
Why?
| | Sequence Analysis, DNA | 3 | 2003 | 771 | 0.050 |
Why?
| | Internet | 1 | 2009 | 656 | 0.050 |
Why?
| | Menstrual Cycle | 1 | 2006 | 145 | 0.050 |
Why?
| | Quetiapine Fumarate | 1 | 2004 | 22 | 0.050 |
Why?
| | Statistics as Topic | 1 | 2005 | 277 | 0.050 |
Why?
| | Dibenzothiazepines | 1 | 2004 | 15 | 0.050 |
Why?
| | Cold Temperature | 1 | 2006 | 207 | 0.050 |
Why?
| | Parietal Lobe | 1 | 2005 | 62 | 0.050 |
Why?
| | Risperidone | 1 | 2004 | 27 | 0.050 |
Why?
| | Visual Pathways | 1 | 2005 | 61 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2007 | 2097 | 0.050 |
Why?
| | Verbal Behavior | 1 | 2004 | 42 | 0.050 |
Why?
| | Area Under Curve | 1 | 2005 | 333 | 0.050 |
Why?
| | Dopamine D2 Receptor Antagonists | 1 | 2003 | 4 | 0.050 |
Why?
| | Dopamine Antagonists | 1 | 2003 | 26 | 0.050 |
Why?
| | Early Diagnosis | 1 | 2005 | 249 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2004 | 312 | 0.050 |
Why?
| | Visual Fields | 1 | 2004 | 116 | 0.050 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2005 | 233 | 0.050 |
Why?
| | Lymphocytes | 2 | 2002 | 379 | 0.050 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2004 | 221 | 0.050 |
Why?
| | Pain Measurement | 1 | 2005 | 567 | 0.050 |
Why?
| | Mental Recall | 2 | 1996 | 224 | 0.050 |
Why?
| | Action Potentials | 6 | 1993 | 498 | 0.050 |
Why?
| | Haloperidol | 1 | 2002 | 27 | 0.050 |
Why?
| | Head | 1 | 2004 | 125 | 0.050 |
Why?
| | Age of Onset | 2 | 2007 | 557 | 0.050 |
Why?
| | Oxygen Consumption | 1 | 2005 | 719 | 0.050 |
Why?
| | Nerve Tissue Proteins | 1 | 2006 | 594 | 0.050 |
Why?
| | Purkinje Cells | 5 | 1988 | 65 | 0.040 |
Why?
| | Chromosome Disorders | 2 | 1999 | 46 | 0.040 |
Why?
| | Radioligand Assay | 1 | 2001 | 34 | 0.040 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2001 | 15 | 0.040 |
Why?
| | Cloning, Molecular | 2 | 2000 | 526 | 0.040 |
Why?
| | Chromosomes, Human, Pair 20 | 1 | 2001 | 17 | 0.040 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2001 | 57 | 0.040 |
Why?
| | Lod Score | 1 | 2001 | 62 | 0.040 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2001 | 36 | 0.040 |
Why?
| | Exons | 3 | 2015 | 361 | 0.040 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2001 | 21 | 0.040 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2001 | 54 | 0.040 |
Why?
| | Visual Cortex | 1 | 2002 | 84 | 0.040 |
Why?
| | Movement | 1 | 2004 | 290 | 0.040 |
Why?
| | Binding, Competitive | 1 | 2001 | 185 | 0.040 |
Why?
| | Chromosome Aberrations | 2 | 1999 | 167 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2007 | 798 | 0.040 |
Why?
| | Hallucinations | 1 | 2001 | 32 | 0.040 |
Why?
| | Cell Count | 1 | 2001 | 315 | 0.040 |
Why?
| | Nutritional Requirements | 1 | 2021 | 78 | 0.040 |
Why?
| | Fornix, Brain | 1 | 2000 | 5 | 0.040 |
Why?
| | Family Health | 1 | 2001 | 192 | 0.040 |
Why?
| | Denervation | 1 | 2000 | 25 | 0.040 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2000 | 48 | 0.040 |
Why?
| | Point Mutation | 2 | 1999 | 232 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2002 | 887 | 0.040 |
Why?
| | Blotting, Western | 3 | 2005 | 1176 | 0.040 |
Why?
| | Multifactorial Inheritance | 1 | 2001 | 242 | 0.040 |
Why?
| | Blotting, Northern | 2 | 2005 | 197 | 0.040 |
Why?
| | Binding Sites | 1 | 2002 | 1306 | 0.040 |
Why?
| | Cocaine | 1 | 2001 | 162 | 0.040 |
Why?
| | Algorithms | 1 | 2007 | 1843 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 973 | 0.040 |
Why?
| | Fathers | 1 | 1999 | 53 | 0.040 |
Why?
| | Genetic Testing | 1 | 2001 | 491 | 0.030 |
Why?
| | Transfer Factor | 1 | 1978 | 3 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 1989 | 588 | 0.030 |
Why?
| | Cell Movement | 1 | 2002 | 950 | 0.030 |
Why?
| | Developmental Disabilities | 1 | 2021 | 280 | 0.030 |
Why?
| | Self Medication | 1 | 1998 | 12 | 0.030 |
Why?
| | Cholinergic Agents | 1 | 1998 | 18 | 0.030 |
Why?
| | Genetics, Population | 1 | 1999 | 225 | 0.030 |
Why?
| | Electric Conductivity | 2 | 1998 | 85 | 0.030 |
Why?
| | Heterozygote | 1 | 1998 | 310 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2001 | 1709 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 1998 | 147 | 0.030 |
Why?
| | Chromosomes, Artificial, Yeast | 1 | 1997 | 5 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2000 | 585 | 0.030 |
Why?
| | Conditioning, Classical | 2 | 2008 | 120 | 0.030 |
Why?
| | Base Sequence | 3 | 2009 | 2119 | 0.030 |
Why?
| | Age Factors | 2 | 2006 | 3321 | 0.030 |
Why?
| | Parents | 2 | 2015 | 1393 | 0.030 |
Why?
| | Memory Disorders | 1 | 1998 | 197 | 0.030 |
Why?
| | Genital Neoplasms, Female | 1 | 1978 | 100 | 0.030 |
Why?
| | In Situ Hybridization | 2 | 2013 | 317 | 0.030 |
Why?
| | Sensory Thresholds | 1 | 1996 | 31 | 0.030 |
Why?
| | Motor Activity | 2 | 1992 | 701 | 0.030 |
Why?
| | Nerve Fibers | 1 | 1995 | 104 | 0.030 |
Why?
| | Receptors, Glutamate | 1 | 1995 | 26 | 0.030 |
Why?
| | Nerve Growth Factors | 1 | 1995 | 79 | 0.030 |
Why?
| | Siblings | 1 | 2015 | 196 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1995 | 326 | 0.030 |
Why?
| | Placenta | 1 | 2021 | 794 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2007 | 6050 | 0.030 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 1994 | 13 | 0.030 |
Why?
| | Cholinergic Fibers | 1 | 1993 | 19 | 0.020 |
Why?
| | Aging | 2 | 1999 | 1983 | 0.020 |
Why?
| | Genetic Engineering | 1 | 1994 | 87 | 0.020 |
Why?
| | Horseradish Peroxidase | 1 | 1993 | 26 | 0.020 |
Why?
| | Orientation | 1 | 1994 | 49 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 1995 | 1030 | 0.020 |
Why?
| | Neuromuscular Junction | 1 | 1994 | 65 | 0.020 |
Why?
| | Synaptic Vesicles | 1 | 1993 | 40 | 0.020 |
Why?
| | Axonal Transport | 1 | 1993 | 26 | 0.020 |
Why?
| | Chronic Disease | 1 | 1999 | 1824 | 0.020 |
Why?
| | Habituation, Psychophysiologic | 1 | 1993 | 57 | 0.020 |
Why?
| | Tissue Banks | 1 | 2013 | 17 | 0.020 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2013 | 45 | 0.020 |
Why?
| | DNA Probes | 1 | 2013 | 57 | 0.020 |
Why?
| | Temporal Lobe | 1 | 1993 | 112 | 0.020 |
Why?
| | Nomifensine | 1 | 1992 | 2 | 0.020 |
Why?
| | HLA-A Antigens | 1 | 2013 | 52 | 0.020 |
Why?
| | Poly A | 1 | 1993 | 49 | 0.020 |
Why?
| | Genes, MHC Class I | 1 | 2013 | 37 | 0.020 |
Why?
| | Receptors, sigma | 1 | 1992 | 3 | 0.020 |
Why?
| | Peptides | 1 | 1999 | 991 | 0.020 |
Why?
| | Gene Expression Profiling | 2 | 2013 | 1790 | 0.020 |
Why?
| | Sympathomimetics | 1 | 1992 | 19 | 0.020 |
Why?
| | Tomography, Emission-Computed | 1 | 1992 | 71 | 0.020 |
Why?
| | Biogenic Monoamines | 1 | 1992 | 17 | 0.020 |
Why?
| | Benzylamines | 1 | 1992 | 44 | 0.020 |
Why?
| | Muscles | 1 | 1994 | 330 | 0.020 |
Why?
| | Tubocurarine | 1 | 1992 | 6 | 0.020 |
Why?
| | Mecamylamine | 1 | 1992 | 6 | 0.020 |
Why?
| | Levodopa | 1 | 1992 | 40 | 0.020 |
Why?
| | N-Methylaspartate | 1 | 1992 | 43 | 0.020 |
Why?
| | Parasympatholytics | 1 | 1992 | 11 | 0.020 |
Why?
| | Injections, Intraventricular | 1 | 1992 | 59 | 0.020 |
Why?
| | Microelectrodes | 1 | 1992 | 49 | 0.020 |
Why?
| | Nervous System | 1 | 1992 | 68 | 0.020 |
Why?
| | Physical Chromosome Mapping | 1 | 2012 | 21 | 0.020 |
Why?
| | Temperature | 1 | 1995 | 633 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 333 | 0.020 |
Why?
| | Genotyping Techniques | 1 | 2012 | 72 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2002 | 8351 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 1997 | 1429 | 0.020 |
Why?
| | DNA Replication | 1 | 1993 | 248 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 1994 | 1361 | 0.020 |
Why?
| | RNA | 2 | 2013 | 925 | 0.020 |
Why?
| | Molecular Sequence Data | 3 | 2003 | 2835 | 0.020 |
Why?
| | Introns | 2 | 2003 | 257 | 0.020 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1994 | 411 | 0.020 |
Why?
| | Protein Biosynthesis | 1 | 1993 | 447 | 0.020 |
Why?
| | Risk Assessment | 1 | 1999 | 3678 | 0.020 |
Why?
| | Adenylate Cyclase Toxin | 1 | 1989 | 6 | 0.020 |
Why?
| | Virulence Factors, Bordetella | 1 | 1989 | 15 | 0.020 |
Why?
| | Pertussis Toxin | 1 | 1989 | 24 | 0.020 |
Why?
| | Receptors, Dopamine | 1 | 1989 | 19 | 0.020 |
Why?
| | Blotting, Southern | 1 | 2009 | 82 | 0.020 |
Why?
| | Autoanalysis | 1 | 1989 | 8 | 0.020 |
Why?
| | Saccharomyces cerevisiae | 1 | 1994 | 584 | 0.020 |
Why?
| | Adenylyl Cyclases | 1 | 1989 | 60 | 0.020 |
Why?
| | Electrochemistry | 1 | 1989 | 69 | 0.020 |
Why?
| | Odds Ratio | 1 | 2012 | 1070 | 0.020 |
Why?
| | Cell Line | 2 | 2009 | 2809 | 0.020 |
Why?
| | Yohimbine | 1 | 1988 | 11 | 0.020 |
Why?
| | Dioxins | 1 | 1988 | 7 | 0.020 |
Why?
| | GTP-Binding Proteins | 1 | 1989 | 150 | 0.020 |
Why?
| | Dioxanes | 1 | 1988 | 11 | 0.020 |
Why?
| | Gene Dosage | 1 | 2009 | 146 | 0.020 |
Why?
| | Receptors, Adrenergic | 1 | 1988 | 20 | 0.020 |
Why?
| | Tyramine | 1 | 1988 | 8 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2009 | 333 | 0.020 |
Why?
| | Pulse | 1 | 1988 | 29 | 0.020 |
Why?
| | Tobacco Use Disorder | 1 | 2010 | 217 | 0.020 |
Why?
| | Fluphenazine | 1 | 1987 | 3 | 0.020 |
Why?
| | Saliva | 1 | 1989 | 256 | 0.020 |
Why?
| | Audiometry, Evoked Response | 1 | 1987 | 15 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 423 | 0.020 |
Why?
| | Stereoisomerism | 1 | 1987 | 102 | 0.020 |
Why?
| | Autoradiography | 2 | 1997 | 64 | 0.020 |
Why?
| | Tyrosine | 1 | 1988 | 217 | 0.020 |
Why?
| | Mutation | 2 | 2015 | 4082 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2007 | 203 | 0.010 |
Why?
| | alpha Catenin | 1 | 2005 | 10 | 0.010 |
Why?
| | Transcription Factors | 1 | 1994 | 1728 | 0.010 |
Why?
| | Suicide | 1 | 1993 | 638 | 0.010 |
Why?
| | ROC Curve | 1 | 2007 | 613 | 0.010 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 50 | 0.010 |
Why?
| | Microarray Analysis | 1 | 2005 | 117 | 0.010 |
Why?
| | Patient Selection | 1 | 2009 | 720 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2006 | 533 | 0.010 |
Why?
| | Nervous System Diseases | 1 | 1987 | 286 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1500 | 0.010 |
Why?
| | Fourier Analysis | 1 | 2002 | 41 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2009 | 1526 | 0.010 |
Why?
| | Artifacts | 1 | 2002 | 142 | 0.010 |
Why?
| | Sex Factors | 1 | 2006 | 2101 | 0.010 |
Why?
| | Diet | 1 | 1988 | 1271 | 0.010 |
Why?
| | Contig Mapping | 1 | 1998 | 10 | 0.010 |
Why?
| | Genes, Duplicate | 1 | 1998 | 4 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1998 | 80 | 0.010 |
Why?
| | Hypersensitivity, Delayed | 1 | 1978 | 30 | 0.010 |
Why?
| | Receptors, Presynaptic | 1 | 1998 | 10 | 0.010 |
Why?
| | Models, Biological | 1 | 2005 | 1758 | 0.010 |
Why?
| | Macaca radiata | 1 | 1997 | 15 | 0.010 |
Why?
| | Autopsy | 1 | 1997 | 96 | 0.010 |
Why?
| | Organ Specificity | 1 | 1997 | 306 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1978 | 278 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 1996 | 384 | 0.010 |
Why?
| | Virus Diseases | 1 | 1978 | 219 | 0.010 |
Why?
| | Species Specificity | 1 | 1996 | 542 | 0.010 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 1995 | 43 | 0.010 |
Why?
| | Gene Amplification | 1 | 1995 | 116 | 0.010 |
Why?
| | Isomerases | 1 | 1994 | 7 | 0.010 |
Why?
| | Protein Disulfide-Isomerases | 1 | 1994 | 12 | 0.010 |
Why?
| | Genes, Fungal | 1 | 1994 | 55 | 0.010 |
Why?
| | DNA Primers | 1 | 1995 | 487 | 0.010 |
Why?
| | Endopeptidases | 1 | 1994 | 80 | 0.010 |
Why?
| | tau Proteins | 1 | 1995 | 111 | 0.010 |
Why?
| | Molecular Biology | 1 | 1994 | 59 | 0.010 |
Why?
| | Cadaver | 1 | 1995 | 302 | 0.010 |
Why?
| | Glycosylation | 1 | 1994 | 175 | 0.010 |
Why?
| | Fungal Proteins | 1 | 1994 | 137 | 0.010 |
Why?
| | Immunotherapy | 1 | 1978 | 669 | 0.010 |
Why?
| | Genetic Vectors | 1 | 1994 | 326 | 0.010 |
Why?
| | DNA | 1 | 1998 | 1418 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1994 | 2088 | 0.000 |
Why?
| | Idazoxan | 1 | 1988 | 1 | 0.000 |
Why?
| | Phentolamine | 1 | 1988 | 19 | 0.000 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 1988 | 19 | 0.000 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1988 | 58 | 0.000 |
Why?
| | Rats, Inbred F344 | 1 | 1988 | 266 | 0.000 |
Why?
| | Desipramine | 1 | 1988 | 10 | 0.000 |
Why?
| | Magnesium | 1 | 1987 | 155 | 0.000 |
Why?
| | DNA-Binding Proteins | 1 | 1994 | 1467 | 0.000 |
Why?
|
|
Freedman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|